We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

AhR Pharma and WARF Sign Exclusive License for ITE

AhR Pharma and WARF Sign Exclusive License for ITE

AhR Pharma and WARF Sign Exclusive License for ITE

AhR Pharma and WARF Sign Exclusive License for ITE

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "AhR Pharma and WARF Sign Exclusive License for ITE"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

AhR Pharmaceuticals Inc. and the Wisconsin Alumni Research Foundation (WARF) have signed an exclusive license agreement for ITE, a natural hormone discovered by University of Wisconsin-Madison researchers with properties helpful in treating cancer, obesity and immune system disorders.

ITE is a hormone for a receptor named aryl hydrocarbon receptor, which mediates a series of important biological and pharmacological processes in the body.

Recent studies on animal models have demonstrated that ITE may be effective in treating cancer and obesity.

The hormone was discovered by a research team led by the university's veteran inventor and biochemist Hector F. DeLuca and including research associate Jiasheng (Jason) Song, who subsequently founded Madison-based AhR Pharmaceuticals and serves as its chief scientific officer.

WARF, the private nonprofit technology transfer organization for UW-Madison, manages the patents related to the ITE discovery.

"We are pleased to make this important announcement," says Song. "WARF is a national leader in university technology transfer due to its long history in managing patents on inventions developed at UW-Madison, an internationally renowned research university."

According to Song, in addition to securing a license through WARF for the intellectual property rights, discoveries made by two research teams have significantly enhanced the possibility for successful development of this unique technology.

He explained that following initial studies completed by DeLuca's team, scientists at AhR Pharmaceuticals conducted additional in vitro and in vivo preclinical studies to verify the feasibility of developing ITE-based therapies.

Song founded AhR Pharmaceuticals to develop ITE into an efficacious and sustainable but low side effect therapeutic agent to combat cancer, obesity and disorders related to imbalanced actions of the immune system.

The short-term focus of the company is developing ITE-based agents as cancer treatments.

"We are excited about the commercial prospects for AhR Pharmaceuticals based on the early results of its preclinical proof-of-concept with ITE," says Mark Stoveken, WARF licensing manager.

Stoveken continued, "The data that has been generated is promising and will enable the company to attract the funds needed for continued development and the eventual establishment of a partnership with a large pharmaceutical organization."